Testosterone Science

FDA, Regulation and Guidelines

Are Testosterone and Testosterone Pellets Safe to Use in Perimenopause and Menopause?

Specific Claim Evaluated

Testosterone pellets are not FDA approved for women and frequently produce supraphysiological testosterone levels; testosterone can be considered for hypoactive sexual desire disorder after other causes are excluded.

Primary Research Supporting or Contradicting the Claim

The consensus statement recommends against pellets and other preparations that produce supraphysiological concentrations and limits the evidence-based indication to hypoactive sexual desire disorder after biopsychosocial assessment (Davis et al., 2019).

Corrected Evidence-Based Interpretation

Accurate.

Rationale for Grade

Although published by a commercial telehealth provider, the article states the regulatory status, the pharmacokinetic concern with pellets and the single evidence-based indication. Its references include a current European guideline. The content is consistent with consensus guidance.

References

  1. Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID
    Supporting excerpt: "The only evidence-based indication for testosterone for women is for HSDD."

Post a Comment

Shared Decision Making

Bring the Evidence to Your Next Consultation

Use our patient resources and questionnaires to prepare questions about symptoms, testing and treatment options for your doctor.